Published in Clin Exp Immunol on August 01, 1983
Not all potently neutralizing, vaccine-induced antibodies to Epstein-Barr virus ensure protection of susceptible experimental animals. Clin Exp Immunol (1986) 0.99
Increased frequency of antibodies to ubiquitous viruses in essential mixed cryoglobulinaemia. Clin Exp Immunol (1986) 0.90
Plasmodium falciparum products enhance human lymphocyte transformation by Epstein-Barr virus. Clin Exp Immunol (1984) 0.89
Detection of S-100 labelled cells in nasopharyngeal carcinoma. J Clin Pathol (1984) 0.79
EBV-positive human sera contain antibodies against the EBV BMRF-2 protein. Virology (2009) 0.76
VIRUS PARTICLES IN CULTURED LYMPHOBLASTS FROM BURKITT'S LYMPHOMA. Lancet (1964) 14.21
Human c-myc onc gene is located on the region of chromosome 8 that is translocated in Burkitt lymphoma cells. Proc Natl Acad Sci U S A (1982) 11.15
A sarcoma involving the jaws in African children. Br J Surg (1958) 10.60
Translocation of the c-myc gene into the immunoglobulin heavy chain locus in human Burkitt lymphoma and murine plasmacytoma cells. Proc Natl Acad Sci U S A (1982) 10.50
Epstein-Barr virus: transformation, cytopathic changes, and viral antigens in squirrel monkey and marmoset leukocytes. Proc Natl Acad Sci U S A (1972) 8.53
Collaborative United Kingdom-Australasian study of cancer in patients treated with immunosuppressive drugs. Br Med J (1979) 5.58
Surface markers on human B and T lymphocytes. II. Presence of Epstein-Barr virus receptors on B lymphocytes. J Exp Med (1973) 5.03
Characteristic chromosomal abnormalities in biopsies and lymphoid-cell lines from patients with Burkitt and non-Burkitt lymphomas. Int J Cancer (1976) 4.35
Cytotoxic effector cells specific for B Cell lines transformed by Epstein-Barr virus are present in patients with infectious mononucleosis. Proc Natl Acad Sci U S A (1975) 4.21
Monoclonal antibody against a 250,000-dalton glycoprotein of Epstein-Barr virus identifies a membrane antigen and a neutralizing antigen. Proc Natl Acad Sci U S A (1980) 3.77
Epidemiological evidence for causal relationship between Epstein-Barr virus and Burkitt's lymphoma from Ugandan prospective study. Nature (1978) 3.73
The cellular basis for viral-induced immunodeficiency: analysis by monoclonal antibodies. J Immunol (1980) 3.49
The transmission of infectious mononucleosis. Am J Med Sci (1955) 3.32
Clonal origin of human tumors. Biochim Biophys Acta (1976) 3.07
Correlation between immunoglobulin light chain expression and variant translocation in Burkitt's lymphoma. Nature (1982) 3.03
Determining the climatic limitations of a children's cancer common in Africa. Br Med J (1962) 3.00
Relationship between Epstein-Barr virus (EBV) DNA and the EBV-determined nuclear antigen (EBNA) in Burkitt lymphoma biopsies and other lymphoproliferative malignancies. Int J Cancer (1974) 2.80
Long-term T-cell-mediated immunity to Epstein-Barr virus. Cancer Res (1981) 2.74
A controlled clinical trial of the efficacy of the hepatitis B vaccine (Heptavax B): a final report. Hepatology (1982) 2.74
EB viral genomes in epithelial nasopharyngeal carcinoma cells. Nat New Biol (1973) 2.71
Protection against Marek's disease by vaccination with a herpesvirus of turkeys. Avian Dis (1970) 2.68
Monoclonal antibodies against the major glycoprotein (gp350/220) of Epstein-Barr virus neutralize infectivity. Proc Natl Acad Sci U S A (1980) 2.59
X-linked recessive progressive combined variable immunodeficiency (Duncan's disease). Lancet (1975) 2.57
Epstein-Barr virus-induced B-cell lymphoma after renal transplantation: acyclovir therapy and transition from polyclonal to monoclonal B-cell proliferation. N Engl J Med (1982) 2.44
Production and characterization of monoclonal antibodies against the Epstein-Barr virus membrane antigen. J Virol (1982) 2.26
Activation of suppressor T cells during Epstein-Barr-virus-induced infectious mononucleosis. N Engl J Med (1979) 2.21
Assay of the infectivity of Epstein-Barr virus by transformation of human leucocytes in vitro. J Gen Virol (1972) 2.18
Immunization against Marek's disease using a live attenuated virus. Nature (1969) 2.02
Oncogenic Herpes viruses. Biochim Biophys Acta (1975) 2.01
Etiology of Burkitt's lymphoma--an alternative hypothesis to a vectored virus. J Natl Cancer Inst (1969) 1.95
Lymphoma development in mice and humans: diversity of initiation is followed by convergent cytogenetic evolution. Proc Natl Acad Sci U S A (1979) 1.90
HLA-restricted T-cell recognition of Epstein-Barr virus-infected B cells. Nature (1980) 1.90
Epstein-Barr virus-induced membrane antigens: immunochemical characterization of Triton X-100 solubilized viral membrane antigens from EBV-superinfected Raji cells. Int J Cancer (1979) 1.89
Polypeptides of the Epstein-Barr virus membrane antigen complex. J Virol (1979) 1.86
Selective transformation of B lymphocytes by E.B. virus. Lancet (1973) 1.84
Fatal infectious mononucleosis in a family. N Engl J Med (1974) 1.73
Correlation between Epstein-Barr virus membrane antigen and three large cell surface glycoproteins. J Virol (1979) 1.71
Pathogenesis of infectious mononucleosis. Lancet (1977) 1.70
Appearance of Epstein-Barr virus-associated antigens in infected Raji cells. Virology (1971) 1.68
A children's cancer dependent on climatic factors. Nature (1962) 1.61
Infectious mononucleosis at the United States Military Academy. A prospective study of a single class over four years. Yale J Biol Med (1974) 1.61
HLA antigen-related restriction of T lymphocyte cytotoxicity to Epstein-Barr virus. Proc Natl Acad Sci U S A (1980) 1.60
Relationship between the Epstein-Barr virus and undifferentiated nasopharyngeal carcinoma: correlated nucleic acid hybridization and histopathological examination. Int J Cancer (1977) 1.58
Immunoglobulin and glucose-6-phosphate dehydrogenase as markers of cellular origin in Burkitt lymphoma. J Exp Med (1973) 1.42
Observations on the EB virus envelope and virus-determined membrane antigen (MA) polypeptides. Int J Cancer (1980) 1.41
Cell-mediated immunity to Epstein-Barr-virus-transformed lymphoblastoid cells in acute infectious mononucleosis. N Engl J Med (1975) 1.36
Malaria and alterations in immune reactivity. Br Med Bull (1982) 1.35
Application of an immunoenzymatic method and an immunoautoradiographic method for a mass survey of nasopharyngeal carcinoma. Intervirology (1980) 1.35
Immunity to malaria. Br Med Bull (1982) 1.34
A review on the epidemiology of nasopharyngeal carcinoma. Int J Cancer (1970) 1.30
Burkitt's lymphoma. N Engl J Med (1981) 1.29
Clonal origin for individual Burkitt tumours. Lancet (1970) 1.27
Absence of allogeneic restriction in human T-cell-mediated cytotoxicity to Epstein-Barr virus-infected target cells. Demonstration of an HLA-linked control at the effector level. J Exp Med (1979) 1.27
Infectious mononucleosis. Epstein-Barr-virus shedding in saliva and the oropharynx. N Engl J Med (1976) 1.26
Serological mass survey for early detection of nasopharyngeal carcinoma in Wuzhou City, China. Int J Cancer (1982) 1.24
Histopathological definition of Burkitt's tumour. Bull World Health Organ (1969) 1.24
Epstein-Barr-virus-induced oncogenesis in immune-deficient individuals. Lancet (1980) 1.24
Epstein-Barr virus-induced diseases in boys with the X-linked lymphoproliferative syndrome (XLP): update on studies of the registry. Am J Med (1982) 1.23
Membrane receptor stripping confirms the association between EBV receptors and complement receptors on the surface of human B lymphoma lines. Int J Cancer (1977) 1.16
Purified Epstein-Barr virus Mr 340,000 glycoprotein induces potent virus-neutralizing antibodies when incorporated in liposomes. Proc Natl Acad Sci U S A (1982) 1.16
Persistent immunologic stimulation as a factor in oncogenesis, with special reference to Burkitt's tumor. Am J Med (1970) 1.15
Nasopharyngeal carcinoma in Alaskan Eskimos Indians, and Aleuts: a review of cases and study of Epstein-Barr virus, HLA, and environmental risk factors. Cancer (1980) 1.14
Immunogenetic aspects of nasopharyngeal carcinoma. IV. Increased risk in Chinese of nasopharyngeal carcinoma associated with a Chinese-related HLA profile (A2, Singapore 2). J Natl Cancer Inst (1976) 1.13
Possibility of EB virus preferentially transforming a subpopulation of human B lymphocytes. Nature (1978) 1.12
Long-term T-cell-mediated immunity to Epstein-Barr virus in renal-allograft recipients receiving cyclosporin A. Lancet (1981) 1.11
Effective subunit vaccines against an enveloped animal virus. Nature (1978) 1.10
Epstein-Barr virus--is it time to develop a vaccine program? J Natl Cancer Inst (1976) 1.10
The relation between the Epstein-Barr virus and infectious mononucleosis, Burkitt's lymphoma and cancer of the postnasal space. East Afr Med J (1969) 1.09
Burkitt's lymphoma outside the known endemic areas of Africa and New Guinea. Int J Cancer (1967) 1.07
Hepatitis B surface antigen-containing liposomes enhance humoral and cell-mediated immunity to the antigen. FEBS Lett (1979) 1.06
Alterations of the immunological specificity of plasma membranes from cells infected with Marek's disease and turkey herpes viruses. J Gen Virol (1974) 1.05
Epstein Barr virus selective T cells in infectious mononucleosis are not restricted to HLA-A and B antigens. J Immunol (1981) 1.05
Epstein-Barr-virus-specific T-cell memory in renal-allograft recipients under long-term immunosuppression. Lancet (1982) 1.02
Nasopharyngeal carcinoma. II. Ultrastructure of normal mucosa, tumor biopsies, and subsequent epithelial growth in vitro. J Natl Cancer Inst (1972) 1.02
Burkitt-type lymphoma in France among non-Hodgkin malignant lymphomas in Caucasian children. Br J Cancer (1982) 1.01
Factors influencing population growth of a colony of cotton-top tamarins. Lab Anim (1983) 1.00
Treatment results of 54 American patients with Burkitt's lymphoma are similar to the African experience. N Engl J Med (1977) 0.99
Comparison of EBV neutralization tests based on abortive infection or transformation of lymphoid cells and their relation to membrane reactive antibodies (anti-MA). Int J Cancer (1974) 0.99
Inhibition of the in vitro outgrowth of Epstein-Barr virus-transformed lymphocytes by thymus-dependent lymphocytes from infectious mononucleosis patients. Clin Exp Immunol (1977) 0.98
Burkitt lymphoma in Papua, New Guinea. Br J Cancer (1967) 0.95
Can Epstein-Barr virus infect and transform all the B-lymphocytes of human cord blood? J Gen Virol (1983) 0.95
Human virus-infected target cells lacking HLA antigens resist specific T-lymphocyte cytolysis. Nature (1977) 0.95
Infectious mononucleosis in children. Evaluation of Epstein-Barr virus-specific serological data. JAMA (1977) 0.94
Evolution of infectious mononucleosis into Epstein-Barr virus carrying monoclonal malignant lymphoma. Lancet (1982) 0.92
Epstein-Barr virus strain- and group-specific antigenic determinants detected by monoclonal antibodies. Int J Cancer (1981) 0.92
Purification and properties of the gp340 component of Epstein-Barr virus membrane antigen in an immunogenic form. J Gen Virol (1983) 0.92
Combined effect of the extracts from Croton tiglium, Euphorbia lathyris or Euphorbia tirucalli and n-butyrate on Epstein-Barr virus expression in human lymphoblastoid P3HR-1 and Raji cells. Cancer Lett (1981) 0.91
Host-determined differences in expression of surface marker characteristics on human and simian lymphoblastoid cell lines transformed by Epstein-Barr virus. Proc Natl Acad Sci U S A (1977) 0.90
Clinical and laboratory evaluation of elderly patients with heterophil-antibody positive infectious mononucleosis. Report of seven patients, ages 40 to 78. Am J Med (1976) 0.90
EBV-related cytotoxicity of Fc receptor negative T lymphocytes separated from the blood of infectious mononucleosis patients. Cancer Lett (1978) 0.88
In vivo induction of anti-herpes simplex virus immune response by type 1 antigens and lipid A incorporated into liposomes. Infect Immun (1982) 0.88
The Epstein-Barr virus receptor is distinct from the C3 receptor. J Gen Virol (1983) 0.88
Relationship between the Epstein-Barr virus genome and nasopharyngeal carcinoma in Caucasian patients. Int J Cancer (1979) 0.87
Nasopharyngeal carcinoma: present status of knowledge. Cancer Res (1974) 0.87
Cellular immune defects to Epstein-Barr virus-determined antigens in young males. Cancer Res (1981) 0.87
Chromosome 14 translocation in African and North American Burkitt's lymphoma;. Int J Cancer (1977) 0.87
Antigenic differences between the membrane antigen polypeptides determined by different EB virus isolates. J Gen Virol (1981) 0.86
Specific marker chromosome 14 in malignant lymphomas. Nature (1976) 0.85
Morphological and virological investigations on cultured Burkitt tumor lymphoblasts (strain Raji). J Natl Cancer Inst (1966) 4.19
An unusual virus in cultures from a human nasopharyngeal carcinoma. J Natl Cancer Inst (1971) 3.30
Comparison of Epstein-Barr virus strains of different origin by analysis of the viral DNAs. J Virol (1980) 3.00
Long-term T-cell-mediated immunity to Epstein-Barr virus. Cancer Res (1981) 2.74
Monoclonal antibodies to Epstein-Barr virus-induced, transformation-associated cell surface antigens: binding patterns and effect upon virus-specific T-cell cytotoxicity. Int J Cancer (1982) 2.55
Studies with Burkitt's lymphoma. Wistar Inst Symp Monogr (1965) 2.51
A re-examination of the Epstein-Barr virus carrier state in healthy seropositive individuals. Int J Cancer (1985) 2.23
T-cell-mediated regression of "spontaneous" and of Epstein-Barr virus-induced B-cell transformation in vitro: studies with cyclosporin A. Cell Immunol (1984) 2.01
HLA-restricted T-cell recognition of Epstein-Barr virus-infected B cells. Nature (1980) 1.90
Various forms of Epstein-Barr virus infection in man: established facts and a general concept. Lancet (1973) 1.73
Pathogenesis of infectious mononucleosis. Lancet (1977) 1.70
Protection of cottontop tamarins against Epstein-Barr virus-induced malignant lymphoma by a prototype subunit vaccine. Nature (1985) 1.64
Biological and biochemical observations on isolates of EB virus from the malignant epithelial cells of two nasopharyngeal carcinomas. Int J Cancer (1979) 1.62
Distinctions between endemic and sporadic forms of Epstein-Barr virus-positive Burkitt's lymphoma. Int J Cancer (1985) 1.62
In vitro analysis of the Epstein-Barr virus: host balance in long-term renal allograft recipients. Int J Cancer (1985) 1.55
Specific immunofluorescence test for the herpes-type EB virus of Burkitt lymphoblasts, authenticated by electron microscopy. J Natl Cancer Inst (1968) 1.54
Respiratory symptoms in patients with treated hypothyroidism and inflammatory bowel disease. Thorax (2003) 1.51
Pilot experiments with EB virus in owl monkeys (Aotus trivirgatus). I Reticuloproliferative disease in an inoculated animal. Int J Cancer (1973) 1.44
Observations on the EB virus envelope and virus-determined membrane antigen (MA) polypeptides. Int J Cancer (1980) 1.41
Epstein-Barr virus-specific cytotoxic T-cell clones restricted through a single HLA antigen. Nature (1982) 1.39
Individual tumors of multifocal EB virus-induced malignant lymphomas in tamarins arise from different B-cell clones. Science (1985) 1.38
Paired Epstein-Barr virus-carrying lymphoma and lymphoblastoid cell lines from Burkitt's lymphoma patients: comparative sensitivity to non-specific and to allo-specific cytotoxic responses in vitro. Int J Cancer (1984) 1.37
Observations on the type of infection by Epstein-Barr virus in peripheral lymphoid cells of patients with infectious mononucleosis. Int J Cancer (1974) 1.37
Congenital failure of automatic control of ventilation, gastrointestinal motility and heart rate. Medicine (Baltimore) (1978) 1.34
Recent progress in Epstein-Barr virus research. Annu Rev Microbiol (1977) 1.31
Cytotoxic T cell recognition of Epstein-Barr virus-infected B cells. I. Specificity and HLA restriction of effector cells reactivated in vitro. Eur J Immunol (1981) 1.30
The EB virus. Annu Rev Microbiol (1973) 1.28
Activation in vitro by BUdR of a productive EB virus infection in the epithelial cells of nasopharyngeal carcinoma. Int J Cancer (1976) 1.26
Cytotoxic T cell recognition of Epstein-Barr virus-infected B cells. III. Establishment of HLA-restricted cytotoxic T cell lines using interleukin 2. Eur J Immunol (1982) 1.24
Quality of information sources about mental disorders: a comparison of Wikipedia with centrally controlled web and printed sources. Psychol Med (2011) 1.22
Pilot experiments with EB virus in owl monkeys (Aotus trivirgatus). II. EB virus in a cell line from an animal with reticuloproliferative disease. Int J Cancer (1973) 1.19
Munchausen syndrome by proxy: considerations in diagnosis and confirmation by video surveillance. Pediatrics (1987) 1.19
Purified Epstein-Barr virus Mr 340,000 glycoprotein induces potent virus-neutralizing antibodies when incorporated in liposomes. Proc Natl Acad Sci U S A (1982) 1.16
Increased small intestinal fermentation is partly responsible for the anti-nutritive activity of non-starch polysaccharides in chickens. Br Poult Sci (1996) 1.15
Varicella-zoster virus as a live vector for the expression of foreign genes. Proc Natl Acad Sci U S A (1987) 1.15
QTc interval prolongation associated with citalopram overdose: a case report and literature review. Clin Neuropharmacol (2001) 1.14
Salivary and serum IgA antibodies to the Epstein-Barr virus glycoprotein gp340: incidence and potential for virus neutralization. Int J Cancer (1991) 1.14
Structure and development of the herpes-types virus of Marek's disease. J Natl Cancer Inst (1968) 1.13
Cytotoxic T cell recognition of Epstein-Barr virus-infected B cells. II. Blocking studies with monoclonal antibodies to HLA determinants. Eur J Immunol (1981) 1.12
Sequential appearance of Epstein-Barr virus nuclear and lymphocyte-detected membrane antigens in B cell transformation. Nature (1981) 1.11
Burkitt lymphoma in New Guinea: establishment of a line of lymphoblasts in vitro and description of their fine structure. J Natl Cancer Inst (1967) 1.11
Epstein-Barr virus gene expression in malignant lymphomas induced by experimental virus infection of cottontop tamarins. J Virol (1989) 1.11
Infection with E.B. virus and rheumatoid arthritis. Lancet (1979) 1.10
Epstein-Barr virus--is it time to develop a vaccine program? J Natl Cancer Inst (1976) 1.10
Identification of heavy metal induced changes in the expression patterns of the translationally controlled tumour protein (TCTP) in the earthworm Lumbricus rubellus1. Biochim Biophys Acta (1998) 1.10
Co-expression of the Epstein-Barr virus BXLF2 and BKRF2 genes with a recombinant baculovirus produces gp85 on the cell surface with antigenic similarity to the native protein. J Gen Virol (1995) 1.10
Reactivation of Epstein-Barr virus-specific cytotoxic T cells by in vitro stimulation with the autologous lymphoblastoid cell line. Int J Cancer (1981) 1.09
Recombinant vaccinia virus expressing Epstein-Barr virus glycoprotein gp340 protects cottontop tamarins against EB virus-induced malignant lymphomas. J Med Virol (1988) 1.09
Soda lime adsorption of isoflurane and enflurane. Anesthesiology (1985) 1.07
Virus in cultured lymphoblasts from a New Guinea Burkitt lymphoma. Br Med J (1967) 1.07
Cytogenetic studies on human lymphoblastoid cell lines from Burkitt's lymphomas and other sources. Int J Cancer (1974) 1.07
Cell-mediated immunosurveillance mechanisms and the pathogenesis of Burkitt's lymphoma. IARC Sci Publ (1985) 1.06
Aspects of the EB virus. Adv Cancer Res (1970) 1.06
The prevalence of naturally occurring antibodies to human syncytial virus in East African populations. J Gen Virol (1980) 1.06
Mechanism of the establishment of Epstein-Barr virus genome-containing lymphoid cell lines from infectious mononucleosis patients: studies with phosphonoacetate. Int J Cancer (1977) 1.04
Mineralized deposits in the thoracic aorta of aged rats: ultrastructural and electron probe x-ray microanalysis study. Exp Gerontol (1980) 1.03
Epstein-Barr-virus-specific T-cell memory in renal-allograft recipients under long-term immunosuppression. Lancet (1982) 1.02
The application of x-ray analysis in the transmission electron analytical microscope (T.E.A.M.) to the quantitative bulk analysis of biological microsamples. J Microsc (1976) 1.01
Factors influencing population growth of a colony of cotton-top tamarins. Lab Anim (1983) 1.00
Not all potently neutralizing, vaccine-induced antibodies to Epstein-Barr virus ensure protection of susceptible experimental animals. Clin Exp Immunol (1986) 0.99
Epstein-Barr virus-specific cytotoxic T cell responses in rheumatoid arthritis patients. Rheumatol Int (1982) 0.99
Interaction of Epstein-Barr virus with leukaemic B cells in vitro. I. Abortive infection and rare cell line establishment from chronic lymphocytic leukaemic cells. Clin Exp Immunol (1982) 0.99
Inhibition of the in vitro outgrowth of Epstein-Barr virus-transformed lymphocytes by thymus-dependent lymphocytes from infectious mononucleosis patients. Clin Exp Immunol (1977) 0.98
Further observations on a human syncytial virus from a nasopharyngeal carcinoma. J Natl Cancer Inst (1974) 0.98
The possible role of viruses in human cancer. Lancet (1971) 0.98
Cross-reactivity of self-HLA-restricted Epstein-Barr virus-specific cytotoxic T lymphocytes for allo-HLA determinants. J Exp Med (1983) 0.97
A theoretical analysis of the barometric method for measurement of tidal volume. Respir Physiol (1978) 0.97
Comparative studies on adult donor lymphocytes infected by EB virus in vivo or in vitro: origin of transformed cells arising in co-cultures with foetal lymphocytes. Int J Cancer (1977) 0.97
Cultivation and fine structure of virus-bearing lymphoblasts from a second New Guinea Burkitt lymphoma: establishment of sublines with unusual cultural properties. Int J Cancer (1968) 0.96
Identification of two T-cell epitopes on the candidate Epstein-Barr virus vaccine glycoprotein gp340 recognized by CD4+ T-cell clones. J Virol (1991) 0.95
Model studies on distributions of blood cells at microvascular bifurcations. Am J Physiol (1985) 0.95
Metal ion trafficking in earthworms. Identification of a cadmium-specific metallothionein. J Biol Chem (2001) 0.95
Isolation of infectious EB virus from the epithelial tumour cells of nasopharyngeal carcinoma. Int J Cancer (1977) 0.95
Preliminary observations on new lymphoblast strains (EB4, EB5) from Burkitt tumours in a British and a Ugandan patient. Br J Cancer (1966) 0.95
Earthworms as biological monitors of cadmium, copper, lead and zinc in metalliferous soils. Environ Pollut (1988) 0.94
Epstein-Barr (EB) virus genome-containing, EB nuclear antigen-negative B-lymphocyte populations in blood in acute infectious mononucleosis. J Gen Virol (1978) 0.94
CD4+ T cells inhibit growth of Epstein-Barr virus-transformed B cells through CD95-CD95 ligand-mediated apoptosis. Int Immunol (1998) 0.94
Observations on the nature of the herpes-type EB virus in cultured Burkitt lymphoblasts, using a specific immunofluorescence test. J Natl Cancer Inst (1968) 0.94
Epstein-Barr virus as the cause of a human cancer. Nature (1978) 0.94
Differences in the accumulated metal concentrations in two epigeic earthworm species (Lumbricus rubellus and Dendrodrilus rubidus) living in contaminated soils. Bull Environ Contam Toxicol (1991) 0.94
A structural investigation of the Epstein-Barr (EB) virus membrane antigen glycoprotein, gp340. J Gen Virol (1984) 0.94
Stimulation of human lymphocytes with irradiated cells of the autologous Epstein-Barr virus-transformed cell line. I. Virus-specific and nonspecific components of the cytotoxic response. Cell Immunol (1982) 0.92
Indirect measurement of Epstein-Barr virus neutralising antibodies by ELISA. J Virol Methods (1998) 0.92
Virus-specific cytotoxic T cell responses are associated with immunity of the cottontop tamarin to Epstein-Barr virus (EBV). Clin Exp Immunol (1996) 0.92
Purification and properties of the gp340 component of Epstein-Barr virus membrane antigen in an immunogenic form. J Gen Virol (1983) 0.92
Absence of infectious Epstein-Barr virus in blood in acute infectious mononucleosis. Nature (1975) 0.92
Stimulation of human lymphocytes with irradiated cells of the autologous Epstein-Barr virus-transformed cell line. II. Cytotoxic response to repeated stimulation. Cell Immunol (1982) 0.91
Replication-defective recombinant adenovirus expressing the Epstein-Barr virus (EBV) envelope glycoprotein gp340/220 induces protective immunity against EBV-induced lymphomas in the cottontop tamarin. J Gen Virol (1993) 0.91
Allospecific T cell recognition of HLA-A2 antigens: evidence for group-specific and subgroup-specific epitopes. Immunogenetics (1985) 0.90
Burkitt's lymphoma: clues to the role of malaria. Nature (1985) 0.90
Accumulation of heavy metals from polluted soils by the earthworm, Lumbricus rubellus: can laboratory exposure of 'control' worms reduce biomonitoring problems? Environ Pollut (1991) 0.89
The Epstein-Barr virus open reading frame BDLF3 codes for a 100-150 kDa glycoprotein. J Gen Virol (1995) 0.89
The major Epstein-Barr virus (EBV) envelope glycoprotein gp340 when incorporated into Iscoms primes cytotoxic T-cell responses directed against EBV lymphoblastoid cell lines. Vaccine (1999) 0.89
Comparative immunogenicity studies on Epstein-Barr virus membrane antigen (MA) gp340 with novel adjuvants in mice, rabbits, and cotton-top tamarins. J Med Virol (1984) 0.89